ClinicalTrials.gg
RecruitingNCT07111559LACUNAR-tPAUpdated Aug 4, 2026

Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial

A Phase 4 interventional study of rt-PA and DAPT in Lacunar Stroke, Stroke and Ischemic Stroke, sponsored by Nippon Medical School. Recruiting at 29 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Nippon Medical School · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are:

Is a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator?

Researchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke).

Participants will:

Take a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.

02

Conditions studied

  • Lacunar Stroke
  • Stroke
  • Ischemic Stroke

Keywords

  • rt-PA
  • tissue-plasminogen activator
  • DAPT
  • dual antiplatelet therapy
  • minor stroke
  • lacunar stroke
03

In context

Stroke, Lacunar

21 studies on the registry are indexed under Stroke, Lacunar; 9 are open to participants now.

This study's planned enrollment of 500 is above the median of 60 across 15 interventional studies indexed under Stroke, Lacunar.

Browse Stroke, Lacunar studies →

Lead sponsor

Nippon Medical School is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Acute ischemic stroke within 4.5 hours from onset. If onset time is unknown because of impaired consciousness or aphasia, use the "last known well" time.
  • A single perforating-artery infarct on brain MRI:

located in the corona radiata, putamen, internal capsule, thalamus, or pons; solitary, mainly round or oval, with a maximum diameter ≤ 20 mm; lesions only in the centrum semiovale are not allowed, but extension from the above sites into the centrum semiovale is allowed.

  • No disability in daily life before the stroke (modified Rankin Scale ≤ 1).
  • National Institutes of Health Stroke Scale (NIHSS) score ≤ 5.
  • Written obtained.

Exclusion criteria

Exclusion Criteria:

  • Antithrombotic therapy considered inappropriate because of active bleeding, low count, or similar conditions.
  • Any to intravenous rt-PA, without blood pressures.
  • ≥ 50 % stenosis or occlusion of the artery responsible for the stroke * (see note below).
  • Diseases that require anticoagulation (e.g., atrial fibrillation, deep-vein thrombosis) *
  • Inability to take medicine orally.
  • Any other reason judged by the principal investigator or co-investigators to make participation inappropriate.

Note: This study targets hyper-acute stroke within 4.5 hours. To avoid treatment delay, items marked with * must be judged using the similar examinations that each site normally performs before rt-PA administration.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    rt-PA

    Drug: rt-PA

  • Experimental
    DAPT

    Drug: DAPT

Interventions

06

What researchers measure

Primary outcomes

  1. Excellent outcome

    Modified Rankin scale score of 0-1

    Time frame: 3 months after stroke

Secondary outcomes

  1. Infarct growth between Day 7 and admission

    Infarct growth between Day 7 and admission on diffusion-weighted imaging

    Time frame: At Day 7

  2. Early neurological deterioration

    Increment in NIHSS score by 2 points or more from admission

    Time frame: At Day 7

  3. NIHSS score on Day 7

    NIHSS score on Day 7

    Time frame: At Day 7

  4. Good outcome

    mRS 0-2 at 3 months from stroke onset

    Time frame: At 3 months

  5. mRS distribution at 3 months

    mRS distribution (assessed by shift analysis) at 3 months from onset

    Time frame: At 3 months

  6. Ischemic stroke recurrence

    Ischemic stroke recurrence during 3 months from onset

    Time frame: At 3 months

  7. Cost effectiveness of DAPT

    Cost effectiveness analysis comparing DAPT to rt-PA

    Time frame: Various (such as at 7 days or 3 months)

Other outcomes

  1. Safety - symptomatic intracerebral hemorrhage

    symptomatic intracerebral hemorrhage

    Time frame: At 24 hours from the initial treatment

  2. Safety - any intracranial bleeding

    any intracranial bleeding

    Time frame: At 14 days from admission

  3. Safety - other hemorrhagic complications

    other hemorrhagic complications

    Time frame: At 14 days from admission

  4. Safety - all-cause mortality

    all-cause mortality

    Time frame: At 3 months

  5. Safety - cerebrovascular death

    cerebrovascular death

    Time frame: At 3 months

07

Study locations

29 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — On reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07111559
Lead sponsor
Nippon Medical School
Collaborators
Japan Research Foundation for Clinical Pharmacology, Takeda Science Foundation - Medical Research Grant
Responsible party
Yuki Sakamoto (Associate Professor, Nippon Medical School) — Principal investigator
First posted
Aug 8, 2025
Start date
Aug 1, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Aug 4, 2026

Study contacts

Yuki Sakamoto
Contact
yuki-sakamoto@nms.ac.jp
+81-3-3822-2131 ext. 24508
Yuki Sakamoto
principal investigator · Nippon Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion